Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904743 · ClinicalTrials.gov registry record · Phase 4
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
A Phase 4 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 141
- Enrollment target
NCT05904743 is a Phase 4 study that has completed, run by Mannkind Corporation. The registered enrollment target is 141 participants.
The verdict
NCT05904743, a Phase 4 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 141 participants
- Enrollment target
Study Summary
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to an insulin regimen of insulin degludec plus inhaled insulin (Afrezza) and CGM or continuation of usual care. The primary outcome of the RCT is at 17 weeks. The RCT will be followed by a 13-week extension phase in which participants in both groups will use the degludec-inhaled insulin regimen.
Interventions
- BIOLOGICAL Afrezza
- BIOLOGICAL Rapid-acting Insulin Analog
- BIOLOGICAL Basal Insulin
- BIOLOGICAL insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05904743
The ClinicalTrials.gov registry entry for NCT05904743 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Afrezza is the first listed.
NCT05904743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05904743 about?
NCT05904743 is a clinical study titled "INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes". INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to ...
What is the current status of trial NCT05904743?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 141 participants. The study started on 2023-07-07. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05904743?
The interventions under investigation include: Afrezza (BIOLOGICAL), Rapid-acting Insulin Analog (BIOLOGICAL), Basal Insulin (BIOLOGICAL), insulin degludec (BIOLOGICAL).
Who is sponsoring clinical trial NCT05904743?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.